

![]() |
|||||||||||||
|
| All | Since 2020 | |
| Citation | 6651 | 4087 |
| h-index | 26 | 21 |
| i10-index | 174 | 83 |
Submit Manuscript
Search
News & Updation
SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS (SNEDDS): FORMULATION PRINCIPLES, MECHANISTIC INSIGHTS, AND BIOPHARMACEUTIC PERSPECTIVES FOR ENHANCED ORAL BIOAVAILABILITY
Dr. Raji M. K.*, Aliya Sheraf, Anjana G., Devapriya B., Henna Reji, Nirbhaja P. K.
ABSTRACT Poor aqueous solubility affects roughly 40% of newly discovered drug candidates, most of them BCS Class II, and remains a principal limitation on oral bioavailability. Self-nanoemulsifying drug delivery systems (SNEDDS) — isotropic, anhydrous pre-concentrates of oil, surfactant, and co-solvent that spontaneously form nanoemulsions (<200 nm) on contact with gastrointestinal fluids — address this limitation by keeping the drug solubilized and thermodynamically active throughout GI transit, thereby increasing dissolution rate and transmembrane flux. This review provides a mechanistically grounded synthesis of SNEDDS science: the biopharmaceutical rationale for their use, the thermodynamic basis of self-emulsification, systematic excipient selection, preparation and characterization methods, and Quality by Design (QbD)-driven optimization. Advanced platforms — solid SNEDDS, supersaturable systems exploiting the spring-and-parachutemechanism, and mucoadhesive/controlled-release SNEDDS — are evaluated for their mechanistic basis and translational limitations. The review concludes by identifying the unresolved in vitro–in vivo correlation (IVIVC) gap, the immaturity of SNEDDS-specific PBPK modeling, and the regulatory and long-term stability data required before SNEDDS can realize their full clinical potential. Keywords: SNEDDS, oral bioavailability, nanoemulsion, BCS Class II drugs, solid SNEDDS. [Download Article] [Download Certifiate] |
